Currently, most of the known targets for anti-atherosclerotic drugs not only focus on lipid storage disease but also on inflammation (which is a common mediator of many risk factors), as well as mechanisms of innate and adaptive immunity in atherosclerosis, molecule scavengers, etc. The success of targeting inflammatory agents (e.g., IL-1β) confirms that the inflammasome pathway may pose a promising pathway for further interventions. Here, IL1B is linked to Lipid storage disease.